🔗 Share this article

While the US undertakes historic revisions to its immunization schedules, an unexpected name has emerged in a surprising turn: Høeg, a US-based sports physician and epidemiologist who first made her name by casting doubt on Covid shots throughout the pandemic and has focused upon possible deaths after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Program

Public health authorities were set to unveil radical changes to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, according to reports – a major change that would place the US at odds with a large portion of the world with no evidence for public health gain. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A Shift at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting specific childhood vaccine recommendations in the US so as to align more similar to Denmark, a nation with universal health coverage and a citizenry roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – typically the purview of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no obvious background in drug development, oversight or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that former directors who headed the center have had.”

CDER has an vast workload at the agency, Woodcock stated.

“The public just pays attention on the new drug program, but the off-patent medication office clears thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and each of these have to be managed,” she explained. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the job, which oversees over 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” the former official said.

Official Statement and Controversial Programs

When asked about concerns about Høeg’s credentials and whether this selection indicates increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “concerns stem from inaccurate presumptions”.

“Her resume is consistent with the functions of her job,” the official stated, noting the months Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's new expedited review system, a contentious one-day therapy clearance system that allegedly troubled her former heads. “How are these medications being chosen for this expedited pathway? Who makes the calls?” Howard said. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards less stringent rules of pharmaceuticals, except for immunizations.”

Public History on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, history, some experts have noted. She authored a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new federal leadership included changing guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of excluding adolescent males from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her beliefs and tailors the evidence to fit the science in a very deceptive, fraudulent fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|